News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
365,379 Results
Type
Article (14473)
Company Profile (114)
Press Release (350792)
Multimedia
Podcasts (37)
Webinars (7)
Section
Business (112645)
Career Advice (458)
Deals (18612)
Drug Delivery (29)
Drug Development (31182)
Employer Resources (50)
FDA (8796)
Job Trends (7678)
News (172764)
Policy (12360)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (6)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (8)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (1)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Genetown Elite (1)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (1324)
Accelerated approval (3)
Allergies (42)
Alliances (34825)
ALS (26)
Alzheimer's disease (517)
Antibody-drug conjugate (ADC) (75)
Approvals (8830)
Artificial intelligence (243)
Autoimmune disease (4)
Automation (13)
Bankruptcy (131)
Best Places to Work (6522)
BIOSECURE Act (7)
Biosimilars (10)
Biotechnology (86)
Bladder cancer (31)
Brain cancer (13)
Breast cancer (119)
Cancer (1061)
Cardiovascular disease (67)
Career advice (409)
Career pathing (9)
CAR-T (106)
Cell therapy (273)
Cervical cancer (10)
Clinical research (24520)
Collaboration (613)
Compensation (113)
Complete response letters (3)
COVID-19 (1149)
CRISPR (38)
C-suite (149)
Cystic fibrosis (47)
Data (1019)
Decentralized trials (1)
Denatured (18)
Depression (16)
Diabetes (107)
Diagnostics (4920)
Digital health (16)
Diversity (4)
Diversity, equity & inclusion (9)
Drug discovery (77)
Drug pricing (13)
Drug shortages (4)
Duchenne muscular dystrophy (23)
Earnings (38755)
Editorial (2)
Employer branding (8)
Employer resources (43)
Events (51452)
Executive appointments (409)
FDA (9450)
Featured Employer (25)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (483)
Gene editing (87)
Generative AI (24)
Gene therapy (175)
GLP-1 (224)
Government (1237)
Grass and pollen (2)
Guidances (29)
Healthcare (9894)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (30)
Indications (13)
Infectious disease (1225)
Inflammatory bowel disease (65)
Inflation Reduction Act (3)
Influenza (32)
Intellectual property (64)
Interviews (51)
IPO (8011)
IRA (8)
Job creations (1439)
Job search strategy (364)
Kidney cancer (4)
Labor market (10)
Layoffs (119)
Leadership (3)
Legal (2521)
Liver cancer (35)
Lung cancer (129)
Lymphoma (65)
Machine learning (5)
Management (17)
Manufacturing (187)
MASH (16)
Medical device (11500)
Medtech (11505)
Mergers & acquisitions (10956)
Metabolic disorders (219)
Multiple sclerosis (29)
NASH (3)
Neurodegenerative disease (31)
Neuropsychiatric disorders (4)
Neuroscience (715)
NextGen: Class of 2025 (3537)
Non-profit (1522)
Northern California (1120)
Now hiring (9)
Obesity (90)
Opinion (77)
Ovarian cancer (39)
Pain (51)
Pancreatic cancer (41)
Parkinson's disease (68)
Partnered (12)
Patents (149)
Patient recruitment (56)
Peanut (26)
People (32794)
Pharmaceutical (16)
Phase I (9040)
Phase II (11063)
Phase III (7179)
Pipeline (575)
Policy (29)
Postmarket research (502)
Preclinical (4104)
Press Release (66)
Prostate cancer (45)
Psychedelics (4)
Radiopharmaceuticals (155)
Rare diseases (137)
Real estate (3366)
Recruiting (20)
Regulatory (9401)
Reports (18)
Research institute (1270)
Resumes & cover letters (68)
Rett syndrome (4)
RNA editing (2)
RSV (23)
Schizophrenia (13)
Series A (88)
Series B (53)
Service/supplier (7)
Sickle cell disease (18)
Southern California (1223)
Special edition (1)
Spinal muscular atrophy (58)
Sponsored (13)
Startups (2507)
State (2)
Stomach cancer (2)
Supply chain (27)
Tariffs (4)
The Weekly (18)
United States (11736)
Vaccines (321)
Venture capitalists (19)
Weight loss (35)
Women's health (17)
Worklife (2)
Date
Today (83)
Last 7 days (428)
Last 30 days (1343)
Last 365 days (17213)
2025 (5477)
2024 (18710)
2023 (22098)
2022 (30813)
2021 (32513)
2020 (30539)
2019 (25798)
2018 (19460)
2017 (18877)
2016 (17763)
2015 (20562)
2014 (15177)
2013 (12743)
2012 (13782)
2011 (14066)
2010 (12826)
Location
Africa (320)
Alabama (41)
Alaska (6)
Arizona (124)
Arkansas (10)
Asia (24094)
Australia (4193)
California (2968)
Canada (1057)
China (252)
Colorado (171)
Connecticut (129)
Delaware (46)
Europe (49230)
Florida (488)
Georgia (138)
Idaho (33)
Illinois (286)
India (13)
Indiana (162)
Iowa (5)
Japan (115)
Kansas (83)
Kentucky (6)
Louisiana (6)
Maine (20)
Maryland (458)
Massachusetts (2060)
Michigan (185)
Minnesota (251)
Mississippi (2)
Missouri (62)
Montana (24)
Nebraska (15)
Nevada (23)
New Hampshire (67)
New Jersey (921)
New Mexico (16)
New York (867)
North Carolina (534)
North Dakota (8)
Northern California (1120)
Ohio (103)
Oklahoma (11)
Oregon (20)
Pennsylvania (607)
Puerto Rico (10)
Rhode Island (25)
South America (508)
South Carolina (20)
South Dakota (1)
Southern California (1223)
Tennessee (62)
Texas (473)
Utah (108)
Virginia (59)
Washington D.C. (11)
Washington State (342)
West Virginia (3)
Wisconsin (38)
365,379 Results for "dynavax technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dynavax Files Preliminary Proxy Statement
April 4, 2025
·
11 min read
Press Releases
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
April 30, 2025
·
13 min read
Press Releases
Dynavax to Participate in Upcoming Investor Conferences
February 26, 2025
·
1 min read
Press Releases
Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
April 23, 2025
·
1 min read
Press Releases
Dynavax Advances Board Refreshment Program
January 28, 2025
·
8 min read
Policy
FDA Rejects Dynavax’s Bid to Expand Use of Hepatitis B Vaccine
Dynavax Technologies announced Tuesday that the FDA issued a Complete Response Letter to the company’s sBLA to include a four-dose regimen of Heplisav-B vaccine for adult hemodialysis patients.
May 14, 2024
·
2 min read
·
Kate Goodwin
Press Releases
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy
February 19, 2025
·
12 min read
Biotech Bay
Dynavax to Present at Upcoming June 2024 Investor Conferences
Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, announced that the Company will present at the following upcoming investor conferences during the month of June.
May 28, 2024
·
1 min read
Drug Development
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company’s investigational vaccine candidate being developed for the prevention of shingles (herpes zoster), a debilitating disease caused by the varicella-zoster virus.
June 27, 2024
·
4 min read
Business
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, reported financial results and provided a business update for the quarter ended March 31, 2024.
May 8, 2024
·
13 min read
1 of 36,538
Next
